Novo Nordisk
NVO
$67.36
Share price
-2.28%
Change (1 day)
-52.36%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
P/S ratio for Novo Nordisk (NVO)
P/S ratio as of July 2025 (TTM): 6.92
According to Novo Nordisk's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 15.1. At the end of 2025 the company had a P/S ratio of 6.94.
P/S ratio history for Novo Nordisk from 2001 to 2025
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2025 | 6.94 | -24.37% |
| 2024 | 9.17 | -32.83% |
| 2023 | 13.7 | 12.11% |
| 2022 | 12.2 | 4.97% |
| 2021 | 11.6 | 40.25% |
| 2020 | 8.27 | 8.58% |
| 2019 | 7.62 | 20.1% |
| 2018 | 6.35 | -16.69% |
| 2017 | 7.62 | 34.24% |
| 2016 | 5.67 | -40.75% |
| 2015 | 9.58 | 31.93% |
| 2014 | 7.26 | 6.89% |
| 2013 | 6.79 | 1.73% |
| 2012 | 6.68 | 22.25% |
| 2011 | 5.46 | -12.63% |
| 2010 | 6.25 | 48.98% |
| 2009 | 4.20 | 17.19% |
| 2008 | 3.58 | -32.96% |
| 2007 | 5.34 | 33.3% |
| 2006 | 4.01 | 20.43% |
| 2005 | 3.33 | -8.68% |
| 2004 | 3.64 | 10.81% |
| 2003 | 3.29 | 24.97% |
| 2002 | 2.63 | -28.15% |
| 2001 | 3.66 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.25 | -67.52% | 🇺🇸 USA |
 Eli Lilly LLY | 14.2 | 105.74% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 1.98 | -71.33% | 🇺🇸 USA |
 Sanofi SNY | 2.47 | -64.34% | 🇫🇷 France |